Revenue is what people want to see. Current market cap is approx $9.8m and Epichem is expected to make $4m this FY. The deal with Elanco removes a lot of the financial burden of running the clinical trials so the cash position of the company is enough to sustain current operations.
I can't explain why people are selling but I know why I am buying.
Revenue is what people want to see. Current market cap is approx...
Add to My Watchlist
What is My Watchlist?
